Final answer:
Jardiance is not recommended for glycemic control in adult patients with T2D who have an eGFR of less than or equal to 30 ml/min/1.73 m^2. This usage is considered off-label due to increased risks and reduced medication efficacy in patients with severe kidney impairment.
Step-by-step explanation:
The question pertains to whether Jardiance (empagliflozin) can be used for glycemic control in adult patients with type 2 diabetes (T2D) who have an estimated glomerular filtration rate (eGFR) of less than or equal to 30 ml/min/1.73 m2. The answer is False. Jardiance is typically not recommended for patients with an eGFR below 30 ml/min/1.73 m2 due to reduced efficacy and increased risk of adverse effects. Chronic kidney disease is classified in stages, and an eGFR lower than 60 ml/min/1.73 m2 for 3 months or more indicates a significant loss of kidney function. Given that Jardiance is a medication that affects the kidneys by promoting glucose excretion, its use in patients with severe renal impairment could lead to further complications.
To provide context, Renal Glycosuria can occur due to a reduced renal threshold for glucose, leading to glucose excretion in urine. This condition can be caused by certain drugs, such as phlorizin, which is known to induce this type of glycosuria.